Pluristem Therapeutics (NASDAQ:PSTI) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Separately, Maxim Group reiterated a buy rating and set a $315.00 target price (up previously from $305.00) on shares of Domino’s Pizza in a research note on Wednesday, April 24th.

Shares of PSTI stock opened at $0.56 on Wednesday. The stock’s fifty day moving average price is $0.60. Pluristem Therapeutics has a 12 month low of $0.50 and a 12 month high of $1.38.

Pluristem Therapeutics (NASDAQ:PSTI) last issued its earnings results on Monday, May 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Analysts expect that Pluristem Therapeutics will post -0.31 EPS for the current year.

Several hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC grew its stake in shares of Pluristem Therapeutics by 12.0% during the first quarter. ARK Investment Management LLC now owns 3,793,249 shares of the biotechnology company’s stock worth $3,679,000 after purchasing an additional 406,155 shares in the last quarter. Nikko Asset Management Americas Inc. acquired a new position in shares of Pluristem Therapeutics during the first quarter worth $900,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Pluristem Therapeutics during the first quarter worth $881,000. Virtu Financial LLC grew its stake in shares of Pluristem Therapeutics by 266.1% during the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 61,858 shares in the last quarter. Finally, Van ECK Associates Corp grew its stake in shares of Pluristem Therapeutics by 38.7% during the fourth quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 14,087 shares in the last quarter. Hedge funds and other institutional investors own 6.00% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Read More: What is a Stop Order?

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.